Moleculin Announces Participation At The 18th Annual Rodman & Renshaw Global Investment Conference In New York City September 11-13th, 2016
NEW YORK, NY and HOUSTON, TX - September 07, 2016 - Moleculin Biotech, Inc. (Nasdaq: MBRX), today announced it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City.
Walter Klemp, Chairman and Acting CEO, of Moleculin, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company. Event: 18th Annual Rodman & Renshaw Global Investment Conference
Date: Tuesday, September 13, 2016
Time: 12:05 - 12:30PM (Eastern Time)
Location: Kennedy I (4th Floor); Lotte New York Palace Hotel in New York City
The presentation will be webcast live. To access the webcast, please visit www.rodmanevents.com. The webcast replay will remain available for 90 days following the live presentation.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. We also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system. The other portfolio targets the metabolism of tumors. For more information, please visit http://www.moleculin.com.
Walter Klemp, Chairman and Acting CEO, of Moleculin, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company. Event: 18th Annual Rodman & Renshaw Global Investment Conference
Date: Tuesday, September 13, 2016
Time: 12:05 - 12:30PM (Eastern Time)
Location: Kennedy I (4th Floor); Lotte New York Palace Hotel in New York City
The presentation will be webcast live. To access the webcast, please visit www.rodmanevents.com. The webcast replay will remain available for 90 days following the live presentation.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. We also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system. The other portfolio targets the metabolism of tumors. For more information, please visit http://www.moleculin.com.